This stock has had a fantastic run in recent months. It's now trading for more than $11, up from less than $4 in March. The stock spiked earlier this month after the company reported second-quarter results that exceeded analyst expectations and revealed information about the launch of its new kidney cancer drug. The stock pulled back from that high, forming a wedge, but broke out of that wedge in recent sessions.
